These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33190106)

  • 1. Regulation of intestinal LDLR by the LXR-IDOL axis.
    van Loon NM; van Wouw SAE; Ottenhoff R; Nelson JK; Kingma J; Scheij S; Moeton M; Zelcer N
    Atherosclerosis; 2020 Dec; 315():1-9. PubMed ID: 33190106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor.
    Zelcer N; Hong C; Boyadjian R; Tontonoz P
    Science; 2009 Jul; 325(5936):100-4. PubMed ID: 19520913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deubiquitylase Inhibition Reveals Liver X Receptor-independent Transcriptional Regulation of the E3 Ubiquitin Ligase IDOL and Lipoprotein Uptake.
    Nelson JK; Cook EC; Loregger A; Hoeksema MA; Scheij S; Kovacevic I; Hordijk PL; Ovaa H; Zelcer N
    J Biol Chem; 2016 Feb; 291(9):4813-25. PubMed ID: 26719329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis.
    Zhang L; Reue K; Fong LG; Young SG; Tontonoz P
    Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2541-6. PubMed ID: 22936343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.
    Scotti E; Hong C; Yoshinaga Y; Tu Y; Hu Y; Zelcer N; Boyadjian R; de Jong PJ; Young SG; Fong LG; Tontonoz P
    Mol Cell Biol; 2011 May; 31(9):1885-93. PubMed ID: 21343340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.
    Hong C; Duit S; Jalonen P; Out R; Scheer L; Sorrentino V; Boyadjian R; Rodenburg KW; Foley E; Korhonen L; Lindholm D; Nimpf J; van Berkel TJ; Tontonoz P; Zelcer N
    J Biol Chem; 2010 Jun; 285(26):19720-6. PubMed ID: 20427281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The LXR-IDOL axis defines a clathrin-, caveolae-, and dynamin-independent endocytic route for LDLR internalization and lysosomal degradation.
    Sorrentino V; Nelson JK; Maspero E; Marques ARA; Scheer L; Polo S; Zelcer N
    J Lipid Res; 2013 Aug; 54(8):2174-2184. PubMed ID: 23733886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Deubiquitylase USP2 Regulates the LDLR Pathway by Counteracting the E3-Ubiquitin Ligase IDOL.
    Nelson JK; Sorrentino V; Avagliano Trezza R; Heride C; Urbe S; Distel B; Zelcer N
    Circ Res; 2016 Feb; 118(3):410-9. PubMed ID: 26666640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct functional domains contribute to degradation of the low density lipoprotein receptor (LDLR) by the E3 ubiquitin ligase inducible Degrader of the LDLR (IDOL).
    Sorrentino V; Scheer L; Santos A; Reits E; Bleijlevens B; Zelcer N
    J Biol Chem; 2011 Aug; 286(34):30190-9. PubMed ID: 21734303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice.
    Hong C; Marshall SM; McDaniel AL; Graham M; Layne JD; Cai L; Scotti E; Boyadjian R; Kim J; Chamberlain BT; Tangirala RK; Jung ME; Fong L; Lee R; Young SG; Temel RE; Tontonoz P
    Cell Metab; 2014 Nov; 20(5):910-918. PubMed ID: 25440061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor.
    Sorrentino V; Zelcer N
    Curr Opin Lipidol; 2012 Jun; 23(3):213-219. PubMed ID: 22510808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced VLDL clearance in Apoe(-/-)Npc1(-/-) mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levels.
    Ishibashi M; Masson D; Westerterp M; Wang N; Sayers S; Li R; Welch CL; Tall AR
    J Lipid Res; 2010 Sep; 51(9):2655-63. PubMed ID: 20562239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
    Liu S; Vaziri ND
    Nephrol Dial Transplant; 2014 Mar; 29(3):538-43. PubMed ID: 24166456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural analysis of the LDL receptor-interacting FERM domain in the E3 ubiquitin ligase IDOL reveals an obscured substrate-binding site.
    Martinelli L; Adamopoulos A; Johansson P; Wan PT; Gunnarsson J; Guo H; Boyd H; Zelcer N; Sixma TK
    J Biol Chem; 2020 Sep; 295(39):13570-13583. PubMed ID: 32727844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idol Depletion Protects against Spontaneous Atherosclerosis in a Hamster Model of Familial Hypercholesterolemia.
    Liang C; Wang X; Peng K; Lai P; Liu Z; Ma J; Chen X; Liu G; Zheng M; Wang Y; Yang H; Liu G; Xian X; Gao M
    Oxid Med Cell Longev; 2022; 2022():1889632. PubMed ID: 35656026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes.
    Engelking LJ; McFarlane MR; Li CK; Liang G
    J Lipid Res; 2012 Jul; 53(7):1359-68. PubMed ID: 22523394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stable liver-specific expression of human IDOL in humanized mice raises plasma cholesterol.
    Ibrahim S; Somanathan S; Billheimer J; Wilson JM; Rader DJ
    Cardiovasc Res; 2016 May; 110(1):23-9. PubMed ID: 26786161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression.
    Dong B; Wu M; Cao A; Li H; Liu J
    Int J Mol Med; 2011 Jan; 27(1):103-10. PubMed ID: 21069265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDOL G51S Variant Is Associated With High Blood Cholesterol and Increases Low-Density Lipoprotein Receptor Degradation.
    Adi D; Lu XY; Fu ZY; Wei J; Baituola G; Meng YJ; Zhou YX; Hu A; Wang JK; Lu XF; Wang Y; Song BL; Ma YT; Luo J
    Arterioscler Thromb Vasc Biol; 2019 Dec; 39(12):2468-2479. PubMed ID: 31597442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.